Thanks for sharing! If the US wants to remain competitive and ensure patients don’t have to travel across the world for treatments, we need to both accept greater risk, recognizing that for many patients the alternative is no treatment, and invest more in promising new therapies, like CAR T, here.
@maxdoppelt
Update: AstraZeneca announced this morning that sunvozertinib is now available in the United States. A major win for the lung cancer community, especially patients with EGFR exon 20 insertion lung cancer who have been waiting for this option.
China approved it in August 2023. The FDA approved it in July 2025. It became commercially available here today. More than three years from its first approval to US availability.
I did not expect this many people to read about my mom. Thank you. If you or someone you love is going through this and doesn’t know where to turn, my messages are open.
https://t.co/yuOkY7a8dp
In January 2025 my mom’s lung cancer spread to her brain. The drug with the best chance of helping her was approved in China but not here.
A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy.
So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years.
The drug was approved in China in 2023. The FDA approved it in July 2025. It still is not for sale here. I know of at least 30 Americans who have made the same trip.
I have been scared to tell this story because I worried it could cost my mom access to the medicine keeping her alive. But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform.
Art Allen at KFF Health News told our story this week. It also ran in The Washington Post.
https://t.co/tHKV3L004L
@BillAckman on China biotech: you described what my family lived through. My mom’s lung cancer drug was approved in China in 2023. The FDA approved it in July 2025 and it still isn’t sold here. We were able to get the drug from China. She’s alive 19 months later. https://t.co/JrIQoZweo5
In January 2025 my mom’s lung cancer spread to her brain. The drug with the best chance of helping her was approved in China but not here.
A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy.
So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years.
The drug was approved in China in 2023. The FDA approved it in July 2025. It still is not for sale here. I know of at least 30 Americans who have made the same trip.
I have been scared to tell this story because I worried it could cost my mom access to the medicine keeping her alive. But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform.
Art Allen at KFF Health News told our story this week. It also ran in The Washington Post.
https://t.co/tHKV3L004L
Max proposes using "Similarity Searches" to match researchers and patients with overlapping data. In 2026, Agentic AI is making this a reality—turning a sea of abstracts into a curated roadmap for a cure.
Support ➡️ https://t.co/JINFHb8KGy
https://t.co/rsWZkZqlLY
Missed out on @AACR? @maxdoppelt and @kyleconcannonmd discuss attending the annual conference! Major scientific advancements are showcased there every year. A must listen if you plan on attending as a patient/advocate! https://t.co/zsIGSTHYtb
Crashing medical conferences for clinical trial access is a bold move. While the jargon is a barrier, being "in the room" builds vital advocacy networks.
Support ➡️ https://t.co/JINFHb8KGy
🔗https://t.co/R0ujwz2vSi
This week, @kyleconcannonMD, @samantham75074, and @maxdoppelt unpack why finding and accessing the right clinical trial is so hard, the regulatory red tape patients often face, and how smarter trial matching could change the future. A must listen! https://t.co/qX3D5a6988
@elonmusk@alx@sama Can @elonmusk and Sam altman get back together? They both seem to want what’s best for the world but may have different opinions on how to get there